JP2016515141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515141A5 JP2016515141A5 JP2016502876A JP2016502876A JP2016515141A5 JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- biomarker
- treatment
- pharmaceutical composition
- absence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 64
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 64
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 64
- 239000000090 biomarker Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 26
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 13
- 101150039808 Egfr gene Proteins 0.000 claims description 12
- 108700021358 erbB-1 Genes Proteins 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 230000004544 DNA amplification Effects 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 238000001574 biopsy Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 4
- 210000003780 hair follicle Anatomy 0.000 claims description 4
- 210000004880 lymph fluid Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 210000002200 mouth mucosa Anatomy 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000011269 treatment regimen Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 229940043275 anti-HER2 drug Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229950010203 nimotuzumab Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 238000004632 predicting treatment efficacy Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000011272 standard treatment Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072638 | 2013-03-14 | ||
| PCT/CN2013/072638 WO2014139131A1 (en) | 2013-03-14 | 2013-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| PCT/US2014/028714 WO2014153018A1 (en) | 2013-03-14 | 2014-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Division JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515141A JP2016515141A (ja) | 2016-05-26 |
| JP2016515141A5 true JP2016515141A5 (enExample) | 2017-04-06 |
| JP6675300B2 JP6675300B2 (ja) | 2020-04-01 |
Family
ID=51535817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502876A Expired - Fee Related JP6675300B2 (ja) | 2013-03-14 | 2014-03-14 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10442862B2 (enExample) |
| JP (2) | JP6675300B2 (enExample) |
| WO (2) | WO2014139131A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10484156B2 (en) * | 2016-11-16 | 2019-11-19 | Qualcomm Incorporated | Search space associated with physical downlink control channel based on channel quality indicators |
| JP7113842B2 (ja) * | 2017-03-29 | 2022-08-05 | クラウン バイオサイエンス，インコーポレイテッド（タイツァン） | 胃がんのセツキシマブ感受性を決定するためのシステムおよび方法 |
| WO2018226863A1 (en) * | 2017-06-06 | 2018-12-13 | University Of Maryland, College Park | Analysis of single cell mechanical phenotyping for metastatic detection |
| CN107582993A (zh) * | 2017-11-10 | 2018-01-16 | 兰志英 | 一种治疗胃癌的药物及其制备方法 |
| CN113164480B (zh) * | 2018-11-14 | 2023-11-28 | 学校法人金泽医科大学 | 用于治疗弥漫性胃癌的药物组合物 |
| CN115197320A (zh) * | 2021-04-07 | 2022-10-18 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751309B1 (en) | 2004-05-27 | 2015-07-22 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| AU2006332212B8 (en) * | 2006-01-04 | 2013-05-30 | Institut National De La Sante Et De La Recherche Medicale | Combination therapy using anti-EGFR and anti-HER2 antibodies |
| US20090017050A1 (en) * | 2007-07-13 | 2009-01-15 | Ventana Medical Systems, Inc. | Egfr antigen-binding molecules and uses thereof |
| EP3216874A1 (en) * | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US9345767B2 (en) * | 2011-05-16 | 2016-05-24 | Taiho Pharmaceutical Co., Ltd. | Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor |
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
-
2013
- 2013-03-14 WO PCT/CN2013/072638 patent/WO2014139131A1/en not_active Ceased
-
2014
- 2014-03-14 WO PCT/US2014/028714 patent/WO2014153018A1/en not_active Ceased
- 2014-03-14 US US14/775,117 patent/US10442862B2/en active Active
- 2014-03-14 JP JP2016502876A patent/JP6675300B2/ja not_active Expired - Fee Related
-
2019
- 2019-11-08 JP JP2019202804A patent/JP2020040959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Joshi et al. | Current treatment and recent progress in gastric cancer | |
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology | |
| De Jesus-Acosta et al. | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma | |
| Bell et al. | Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| Bollschweiler et al. | Current and future treatment options for esophageal cancer in the elderly | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Carlson et al. | NCCN Task Force Report: adjuvant therapy for breast cancer | |
| Locati et al. | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact | |
| Iveson et al. | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | |
| Fuchs et al. | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| JP2016515141A5 (enExample) | ||
| De Mattos-Arruda et al. | Translating neoadjuvant therapy into survival benefits: one size does not fit all | |
| Dakhel et al. | S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer | |
| Höller et al. | Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now? | |
| Muller et al. | Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma | |
| Souche et al. | First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Fleischmann et al. | ACO/ARO/AIO-21-Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
| Improta et al. | Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity | |
| JP2019519772A (ja) | Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 | |
| Caponigro et al. | A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck | |
| Stinchcombe et al. | Bevacizumab in the treatment of non-small-cell lung cancer |